沒(méi)有完全理解這個(gè)機(jī)制。一般來(lái)說(shuō)，雌激素應(yīng)該是不利的，應(yīng)該用雌激素拮抗劑才對(duì)，為什么用受體激動(dòng)劑TTC-352來(lái)治療乳腺癌呢？看了一下原文，這樣描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 確實(shí)是雌激素受體部分激動(dòng)劑(ShERPA)，以后再多研究研究
2020-08-29
沒(méi)有完全理解這個(gè)機(jī)制。一般來(lái)說(shuō)，#雌激素#應(yīng)該是不利的，應(yīng)該用雌激素拮抗劑才對(duì)，為什么用受體激動(dòng)劑#TTC-352#來(lái)治療#乳腺癌#呢？看了一下原文，這樣描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 確實(shí)是雌激素受體部分激動(dòng)劑(ShERPA)，以后再多研究研究
2020-08-29
